US2016051572A1PendingUtilityA1

Trauma therapy

44
Assignee: HIBERNATION THERAPEUTICS A KF LLCPriority: Jul 25, 2006Filed: Aug 13, 2015Published: Feb 25, 2016
Est. expiryJul 25, 2026(expired)· nominal 20-yr term from priority
Inventors:Geoffrey Phillip Dobson
A61P 9/10A61P 9/00A61P 9/02A61P 43/00A61P 7/08A61K 9/0019A61K 31/4045A61P 23/02A61K 31/167A61K 31/7076A61K 45/06A61K 33/06A61K 47/02A61K 38/28A61P 17/02
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) a local anaesthetic. Also provided is a composition for reducing injury to cells, tissues or organs of a body following trauma including: (i) and (ii). The composition may be hypertonic.

Claims

exact text as granted — not AI-modified
1 - 9 . (canceled) 
     
     
         10 . A method of reducing injury to cells, tissues or organs in a person suffering from cardiogenic shock as a consequence of trauma comprising:
 administering a composition to the person following the trauma, the composition comprising:
 (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and 
 (ii) a local anaesthetic, 
   wherein the person is suffering injury to cells, tissues or organs resulting from the cardiogenic shock as a consequence of the trauma and administering the composition thereby reduces the injury to cells, tissues or organs.   
     
     
         11 . The method according to  claim 10 , wherein the composition is hypertonic. 
     
     
         12 . The method according to  claim 11 , wherein the composition comprises 7.5% saline. 
     
     
         13 . The method according to  claim 10 , wherein the composition is administered as one-shot. 
     
     
         14 . The method according to  claim 10 , wherein the composition is administered directly to the tissue or organ. 
     
     
         15 . The method according to  claim 10 , wherein component (i) is adenosine. 
     
     
         16 . The method according to  claim 10 , wherein the local anaesthetic is lignocaine. 
     
     
         17 . The method according to  claim 15 , wherein the local anaesthetic is lignocaine. 
     
     
         18 . The method according to  claim 10 , wherein the composition further comprises divalent magnesium cations. 
     
     
         19 . The method according to  claim 18 , wherein the concentration of magnesium cations is up to about 20 mM. 
     
     
         20 . The method according to  claim 10 , wherein the treatment further comprises the step of subsequently administering to the person a second composition, comprising:
 (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and   (ii) a local anaesthetic.   
     
     
         21 . The method according to  claim 20 , wherein the second composition is administered continuously by infusion. 
     
     
         22 . The method of  claim 10 , wherein the composition further comprises an antioxidant. 
     
     
         23 . The method of  claim 22 , wherein the antioxidant is melatonin. 
     
     
         24 . The method of  claim 10 , wherein the composition further comprises an impermeant. 
     
     
         25 . The method of  claim 24 , wherein the impermeant is insulin. 
     
     
         26 . The method according to  claim 10 , wherein (i) is adenosine and (ii) is lignocaine. 
     
     
         27 . The method according to  claim 20 , wherein (i) is adenosine and (ii) is lignocaine.

Join the waitlist — get patent alerts

Track US2016051572A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.